Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Sanofi (OtherSNYNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRNResearch Report) and Sanofi (SNYNFResearch Report) with bullish sentiments.

BioMarin Pharmaceutical (BMRN)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on BioMarin Pharmaceutical, with a price target of $147.00. The company’s shares closed last Wednesday at $80.31.

According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of -8.4% and a 30.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Pacira Pharmaceuticals, and Aquestive Therapeutics.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $112.75, implying a 41.0% upside from current levels. In a report issued on April 25, Morgan Stanley also upgraded the stock to Buy with a $113.00 price target.

See the top stocks recommended by analysts >>

Sanofi (SNYNF)

Goldman Sachs analyst Keyur Parekh maintained a Buy rating on Sanofi today and set a price target of EUR127.00. The company’s shares closed last Tuesday at $107.69.

Parekh has an average return of 6.9% when recommending Sanofi.

According to TipRanks.com, Parekh is ranked #1591 out of 7888 analysts.

Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $118.58, representing an 8.7% upside. In a report issued on April 18, Jefferies also maintained a Buy rating on the stock with a EUR135.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed